& getting an additional 5 year exclusivity and getting a US promoter for MTFB has really derisked this share for me.It appears that the top boys know Ipriclam works and is 16 times better than it current competitor. I think the US will eat this up..antibiotic resistance is a worldwide problem.
AMP have 28.23m shares now and 20.19m upon CL conversion [around 37% of MTFB]. Forget the other partner companies, forget the US$40m that Access won but is being appealed - result before year end?, forget Datatern and the 100 licences, ,forget the licence claim against a Fortune 500 company, forget sports drinks thingy, forget the carry value of all this is not included in the NPV, & forget KMK - AMP will still be big without any of the above.
AMP is a safehaven from the increasing volatility of the markets. .. For those new to the company, have a read of the interims here and MTFB RNS over the weekend - GL
Datafeed and UK data supplied by NBTrader and Digital Look.
While London South East do their best to maintain the high quality of the information displayed on this site,
we cannot be held responsible for any loss due to incorrect information found here. All information is provided free of charge, 'as-is', and you use it at your own risk.
The contents of all 'Chat' messages should not be construed as advice and represent the opinions of the authors, not those of London South East Limited, or its affiliates.
London South East does not authorise or approve this content, and reserves the right to remove items at its discretion.